Pfizer Inc. is to pay $810m to buy Swiss rare disease company Therachon AG, to obtain its asset TA-46 for achondroplasia, the most common form of short-limbed dwarfism.
The deal terms mean that Pfizer will pay $340m upfront, with an added $470m in additional payments dependent on TA-46...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
